Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Long-Term Assets
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Long-Term Assets Peer Comparison
600436
600276
000538
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Other Long-Term Assets
¥349.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Long-Term Assets
¥217.4m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
29%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Long-Term Assets
¥705.6m
|
CAGR 3-Years
41%
|
CAGR 5-Years
26%
|
CAGR 10-Years
35%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Long-Term Assets
¥420.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Long-Term Assets
¥84.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
349.6m
CNY
Based on the financial report for Mar 31, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Long-Term Assets amounts to 349.6m CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
71%
Over the last year, the Other Long-Term Assets growth was 181%. The average annual Other Long-Term Assets growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 21% over the past three years , 71% over the past five years .
You don't have any saved screeners yet
